Effects of paroxetine and gabapentin on hot flashes in postmenopausal women

A comparative study of the effects of paroxetine and gabapentin in the treatment of hot flashes in postmenopausal women

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201704143461N8

Enrollment

Registered

2017-10-22

Start date

2017-05-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Flushing. Flushing

Interventions

Intervention 1: Group A: Each day, up to 8 weeks (a 56-day course), received 600 mg capsule of gabapentin. Intervention 2: Group B: Each day, up to 8 weeks (a 56-day course), received 600 mg capsule o

Treatment - Drugs

Group A: Each day, up to 8 weeks (a 56-day course), received 600 mg capsule of gabapentin.

Group B: Each day, up to 8 weeks (a 56-day course), received 600 mg capsule of paroxetine.

Eligibility

Sex/Gender

Female

Age

15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: The Women who have hot flashes with sweats on average 7 times or more and have more than 12 months of menstrual cessation. Exclusion criteria: Women with a history of chemotherapy; radiation therapy; depression; systemic diseases; liver disease; cancer and diseases that cause hormonal disorders.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Flushing. Timepoint: Before and after treatment. Method of measurement: Based on MRS questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFirozeh Vaysi

Kermanshah University of Medical Sciences

f_veisi@kums.ac.ir+98 83 3427 6309

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026